Payment overview · 2025
General Payments
$1,405.66
56 reported records · 20 companies
Healthcare provider profile · identity verified
Shuo Zhou
Allopathic & Osteopathic Physicians|Family Medicine · DOWNEY, CA · NPI 1184099954
Verified facts
What the public records show
CMS Open Payments records show Shuo Zhou received $1,405.66 in general payments during 2025 across 56 reported records.
ABBVIE INC. accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Entresto, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Ozempic, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 402 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 314 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 402 claims for Linzess by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $207.34 | 14.8% | 10 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $184.07 | 13.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $162.77 | 11.6% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $106.49 | 7.6% | 5 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $79.43 | 5.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.72 | 5.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $75.18 | 5.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $71.59 | 5.1% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $65.42 | 4.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.00 | 4.1% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.62 | 4.0% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $54.35 | 3.9% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $38.63 | 2.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.57 | 2.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.87 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.81 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.62 | 1.7% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $21.93 | 1.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.54 | 1.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.71 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,405.66 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $184.07 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $151.48 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $148.79 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $106.49 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $82.17 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $80.60 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $79.43 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $75.18 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $71.59 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.39 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $56.62 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $54.35 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.10 | 1 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.76 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.92 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $26.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $8.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $8.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 145 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 60 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 314 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 85 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 303 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 177 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 402 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
145 | 48 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
402 | 96 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
89 | 59 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
100 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
314 | 79 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
177 | 36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
303 | 53 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
402 | 96 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1267 | 342 |
| Amlodipine Besylate | Amlodipine Besylate | 1196 | 304 |
| Losartan Potassium | Losartan Potassium | 916 | 253 |
| Vascepa | Icosapent Ethyl | 857 | 182 |
| Metformin Hcl | Metformin Hcl | 649 | 169 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 621 | 201 |
| Montelukast Sodium | Montelukast Sodium | 615 | 202 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 587 | 149 |
| Azelastine Hcl | Azelastine Hcl | 521 | 157 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 504 | 160 |
| Azithromycin | Azithromycin | 502 | 304 |
| Tamsulosin Hcl | Tamsulosin Hcl | 458 | 123 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 448 | 185 |
| Diclofenac Sodium | Diclofenac Sodium | 447 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 439 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 434 | 111 |
| Clopidogrel | Clopidogrel Bisulfate | 412 | 101 |
| Linzess | Linaclotide | 402 | 96 |
| Gabapentin | Gabapentin | 386 | 135 |
| Famotidine | Famotidine | 373 | 125 |
| Lidocaine | Lidocaine | 348 | 82 |
| Januvia | Sitagliptin Phosphate | 320 | 47 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 317 | 67 |
| Farxiga | Dapagliflozin Propanediol | 314 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 305 | 99 |
| Alendronate Sodium | Alendronate Sodium | 304 | 95 |
| Jardiance | Empagliflozin | 303 | 53 |
| Icosapent Ethyl | Icosapent Ethyl | 292 | 110 |
| Amoxicillin | Amoxicillin | 279 | 156 |
| Meloxicam | Meloxicam | 272 | 95 |
| Meclizine Hcl | Meclizine Hcl | 269 | 120 |
| Memantine Hcl Er | Memantine Hcl | 266 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 259 | 99 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 254 | 98 |
| Omeprazole | Omeprazole | 254 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 253 | 66 |
| Mupirocin | Mupirocin | 241 | 95 |
| Finasteride | Finasteride | 240 | 51 |
| Atenolol | Atenolol | 203 | 51 |
| Eliquis | Apixaban | 202 | 25 |
| Allopurinol | Allopurinol | 200 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 198 | 80 |
| Baclofen | Baclofen | 193 | 75 |
| Celecoxib | Celecoxib | 186 | 76 |
| Lisinopril | Lisinopril | 185 | 49 |
| Restasis | Cyclosporine | 181 | 49 |
| Kerendia | Finerenone | 177 | 36 |
| Metoclopramide Hcl | Metoclopramide Hcl | 161 | 45 |
| Fluocinonide | Fluocinonide | 157 | 55 |
| Pioglitazone Hcl | Pioglitazone Hcl | 152 | 28 |
| Prednisone | Prednisone | 152 | 64 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 151 | 53 |
| Creon | Lipase/Protease/Amylase | 145 | 48 |
| Simvastatin | Simvastatin | 144 | 37 |
| Lorazepam | Lorazepam | 143 | 38 |
| Cyclosporine | Cyclosporine | 141 | 42 |
| Myrbetriq | Mirabegron | 139 | 30 |
| Memantine Hcl | Memantine Hcl | 132 | 31 |
| Ketoconazole | Ketoconazole | 130 | 37 |
| Lansoprazole | Lansoprazole | 128 | 41 |
| Ammonium Lactate | Ammonium Lactate | 122 | 44 |
| Mometasone Furoate | Mometasone Furoate | 114 | 48 |
| Carvedilol | Carvedilol | 111 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 110 | 28 |
| Sildenafil Citrate | Sildenafil Citrate | 110 | 22 |
| Nifedipine Er | Nifedipine | 108 | 26 |
| Dexlansoprazole Dr | Dexlansoprazole | 105 | 34 |
| Raloxifene Hcl | Raloxifene Hcl | 103 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 33 |
| Clonidine Hcl | Clonidine Hcl | 101 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 25 |
| Brilinta | Ticagrelor | 100 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 73 |
| Clonidine | Clonidine | 99 | 17 |
| Ezetimibe | Ezetimibe | 97 | 31 |
| Tradjenta | Linagliptin | 96 | 14 |
| Donepezil Hcl | Donepezil Hcl | 94 | 20 |
| Glimepiride | Glimepiride | 90 | 21 |
| Clobetasol Propionate | Clobetasol Propionate | 89 | 30 |
| Prolia | Denosumab | 89 | 59 |
| Dutasteride | Dutasteride | 87 | 25 |
| Furosemide | Furosemide | 87 | 39 |
| Gemtesa | Vibegron | 85 | 21 |
| Glipizide | Glipizide | 85 | 17 |
| Irbesartan | Irbesartan | 84 | 18 |
| Hydrocortisone | Hydrocortisone | 82 | 35 |
| Procto-Med Hc | Hydrocortisone | 81 | 36 |
| Felodipine Er | Felodipine | 80 | 22 |
| Levetiracetam | Levetiracetam | 80 | suppressed |
| Nitroglycerin | Nitroglycerin | 79 | 41 |
| Alprazolam | Alprazolam | 76 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 15 |
| Latanoprost | Latanoprost | 73 | 18 |
| Cephalexin | Cephalexin | 72 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 19 |
| Fenofibrate | Fenofibrate | 71 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 69 | 20 |
| Methimazole | Methimazole | 67 | 13 |
| Colchicine | Colchicine | 64 | 21 |
| Nateglinide | Nateglinide | 61 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 61 | 14 |
| Entresto | Sacubitril/Valsartan | 60 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 23 |
| Potassium Chloride | Potassium Chloride | 60 | 13 |
| Rybelsus | Semaglutide | 60 | 12 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 60 | 22 |
| Ozempic | Semaglutide | 58 | suppressed |
| Clonazepam | Clonazepam | 57 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 55 | suppressed |
| Licart | Diclofenac Epolamine | 55 | 16 |
| Pregabalin | Pregabalin | 55 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 18 |
| Midodrine Hcl | Midodrine Hcl | 53 | 15 |
| Propranolol Hcl | Propranolol Hcl | 53 | 17 |
| Terazosin Hcl | Terazosin Hcl | 53 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 21 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 51 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 50 | 23 |
| Metronidazole | Metronidazole | 50 | 17 |
| Trazodone Hcl | Trazodone Hcl | 50 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 14 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 49 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 48 | 11 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 48 | 24 |
| Temazepam | Temazepam | 48 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 47 | 16 |
| Ibuprofen | Ibuprofen | 47 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 32 |
| Febuxostat | Febuxostat | 46 | suppressed |
| Folic Acid | Folic Acid | 45 | 22 |
| Olanzapine | Olanzapine | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | 25 |
| Loperamide | Loperamide Hcl | 44 | 31 |
| Repaglinide | Repaglinide | 44 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 43 | 13 |
| Zenpep | Lipase/Protease/Amylase | 43 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 42 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 41 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | 14 |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Scopolamine | Scopolamine | 40 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 40 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 12 |
| Tramadol Hcl | Tramadol Hcl | 39 | 17 |
| Diclofenac Epolamine | Diclofenac Epolamine | 38 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 37 |
| Ursodiol | Ursodiol | 38 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 36 | 18 |
| Ciclopirox | Ciclopirox Olamine | 35 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 34 | suppressed |
| Tobradex St | Tobramycin/Dexamethasone | 34 | 16 |
| Digoxin | Digoxin | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 31 | 11 |
| Trulance | Plecanatide | 31 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Valsartan | Valsartan | 30 | 16 |
| Bethanechol Chloride | Bethanechol Chloride | 29 | suppressed |
| Ciclopirox | Ciclopirox | 29 | 11 |
| Glipizide Er | Glipizide | 29 | 11 |
| Clotrimazole | Clotrimazole | 28 | 11 |
| Diazepam | Diazepam | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 16 |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 27 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 27 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Belsomra | Suvorexant | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 12 |
| Lactulose | Lactulose | 25 | 11 |
| Xiidra | Lifitegrast | 25 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 24 | 11 |
| Naproxen | Naproxen | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 23 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Fycompa | Perampanel | 21 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Acetic Acid | Acetic Acid | 20 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 19 |
| Methylprednisolone | Methylprednisolone | 20 | 15 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | 13 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Edarbi | Azilsartan Medoxomil | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Propylthiouracil | Propylthiouracil | 14 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Plavix | Clopidogrel Bisulfate | 12 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Benzonatate | Benzonatate | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,405.66 · 56 records | ABBVIE INC. | ACTHAR, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, ENTRESTO, EVENITY, FARXIGA, GEMTESA, Grastek, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, LINZESS, Odactra, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Ragwitek, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tymlos, UBRELVY, VRAYLAR, ZENPEP, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error